Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab perioperative therapy for esophageal and gastroesophageal junction cancer
ChiCTR2100051013Phase 4Recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC) and esophagogastric junction cancer (3 arms), sponsored by Shanxi Cancer Hospital. Primary endpoints: Major pathological response rate, R0 resection rate and 1 more. Started Sep 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)esophagogastric junction cancer
Beyond the preview
Go deeper on ChiCTR2100051013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051013.